Please login to the form below
vaccine sales
This page shows the latest vaccine sales news and features for those working in and with pharma, biotech and healthcare.
Annual COVID-19 jabs likely, says Pfizer head
Perhaps inevitably, considering that Pfizer expects to ring up $35bn of sales for its COVID-19 vaccine this year alone, Bourla defended the right of the company to make a profit ... He added that the vaccine was sold to low-income countries at no profit
Latest news
-
Pfizer's 2021 revenue predictions soar to $82bn
Strong third-quarter revenues of $24.1bn lifted by sales of its BioNTech-partnered COVID-19 vaccine Comirnaty see Pfizer raise its 2021 revenue guidance to $82bn. ... its sales by 30%, driven by first-line use in advanced renal cell carcinoma.
-
Pfizer starts RSV trial ahead of winter season
In a recent financial update, GSK stated it expected peak sales for the vaccine of $4bn. ... Janssen also has a phase 3 trial looking at its vaccine candidate, Ad26.RSV.preF.
-
Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’
Most notably, sales of the company’s human papillomavirus (HPV) vaccine Gardasil increased by 88% to $1.2bn, primarily due to recovery from the pandemic and strong demand in the US. ... Sales of the nine-valent HPV vaccine took a major hit in the early
-
GSK beats expectations thanks to strong vaccine sales in Q2
The boost came from strong sales of its vaccine business, which was up 39% to £1.6bn thanks to the strong growth (46%) of its meningitis vaccine. ... However, sales of its shingles jab Shingrix increased by only 1% on a constant currency basis, although
-
AZ raises full-year guidance after completing Alexion acquisition in Q2
In Q2, revenue increased by 17% to $7.3bn when excluding COVID-19 vaccine sales. ... Sales of its COVID-19 vaccine – sold under the Vaxzevria brand name in Europe – reached $894m in Q2, up from Q1 sales of $275m.
More from news
Approximately 0 fully matching, plus 67 partially matching documents found.
Latest Intelligence
-
The good, the bad and the ugly
This was driven largely by higher-than-expected sales of its pneumonia vaccine, Prevnar, which accounted for more than 11% of its total revenues in the third quarter of 2017. ... Its closest rival, Novartis, also grew impressively - boasting a projected
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Sanofi halts recruitment for trials assessing MS treatment
- bluebird bio reveals plans to launch two gene therapies
- Eli Lilly to make bebtelovimab commercially available to US states from August
- ONS records a continued fall in UK COVID-19 infections
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
- Biogen and Eisai share latest lecanemab results for the treatment of Alzheimer's disease
- Engaging KOLs and Gaining Insights in Pharma's New Normal
- That ‘don’t’ impress me much
- Bristol Myers Squibb and GentiBio in $1.9bn deal to develop IBD therapies
- Novartis’ Pluvicto receives MHRA marketing authorisation to treat advanced prostate cancer
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- ONS data reveals significant decrease in COVID-19 antibodies
PMHub
Say Communications
Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...
Latest intelligence
- The communication challenge of helping he next generation to be healthier
- As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
- Are we losing sight of what the democratisation of healthcare really looks like?
- We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
- How the Royal Society’s EiR programme can help to drive UK innovation
- ...
